Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer expanded its Lyme disease vaccine partnership with Valneva on Wednesday, taking an 8.1% equity stake in the French biotech and restructuring milestones…
Pfizer is putting fresh capital into the troubled Lyme disease vaccine space with a 95 million dollar equity investment in Valneva, signaling commitment to…
Pfizer is making a fresh equity investment in Valneva worth approximately 90.5 million euros to support advancement of VLA15, the only Lyme disease vaccine…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Pfizer and Valneva updated their Lyme disease vaccine collaboration on June 22, 2022: Pfizer made a EUR90.5M (~$95M) equity investment for an 8.1% stake in Valneva, with up to $168M in remaining development/early-commercialization milestones, up to $100M in cumulative sales milestones, and tiered 14%-22% royalties, alongside initiation of the Phase 3 VALOR study (VLA15) in Q3 2022. The program then weathered a major setback: on February 17, 2023 Pfizer discontinued roughly half of the U.S. participants after Good Clinical Practice violations were found at a third-party clinical-trial site operator (not a vaccine safety or adverse-event issue). VALOR continued, and on March 22-23, 2026 Pfizer and Valneva reported strong Phase 3 efficacy for the six-valent OspA-based candidate (now PF-07307405 / LB6V, formerly VLA15): 73.2% efficacy from 28 days post-dose 4 (season 2) and 74.8% from 1 day post-dose 4, with the vaccine well tolerated and no safety concerns identified. Pfizer stated it is planning submissions to regulatory authorities (FDA/EMA). A positive readout materially de-risks what would be the first Lyme disease vaccine since LYMErix was withdrawn in 2002.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Valneva SE (VLA15 collaboration update) (this deal) | 2022 | $363M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Infectious Disease deals